Evidence map›Paper›PMID 26044191›Full record

ArticleInternational journal of oncology2015

NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.

Kimberly A Foster, Esther P Jane, Daniel R Premkumar, Alejandro Morales, Ian F Pollack

Open access · bronzeAbstract read
In one paragraph

Article in International journal of oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  2. Review
  3. Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.International journal of molecular sciences · 2021
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kimberly A FosterDepartment of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA.
Esther P JaneDepartment of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA.
Daniel R PremkumarDepartment of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA.
Alejandro MoralesUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Ian F PollackDepartment of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · US

Funding

Vector delivery to modify the brain tumor and its microenvironmentP01NS040923 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLORIOSO, JOSEPH C · 2002 to 2012
$12.7M
NINDS NIH HHS P01 NS040923NINDS NIH HHS P01NS40923
6 · The paper itself

Abstract

We previously observed that glioma cells are differentially sensitive to TRAIL-induced toxicity. Based on our observation that TRAIL-resistant glioma cell lines typically exhibited high levels of Akt activation, we hypothesized that inhibition of Akt signaling using the PI3 kinase inhibitor NVP-BKM120 could promote TRAIL-induced apoptosis in gliomas. We assessed this combination in established and primary cultured glioma cells. Combination treatment led to significant cellular death when compared to either drug alone, but had no effect in normal human astrocytes, and demonstrated activation of the caspase cascade. This enhanced apoptosis appears dependent upon the loss of mitochondrial membrane potential and the release of Smac/DIABLO, AIF and cytochrome c into the cytosol. The upregulation of Noxa and sequestration of Mcl-1 by Noxa were important factors for cell death. Knockdown of Noxa abrogated apoptosis and suggested dependency on Noxa in combination-induced apoptosis. BKM120 upregulated cell surface expression of death receptor 5 (DR5), but did not increase levels of the other major TRAIL receptor, death receptor 4 (DR4). This study demonstrates that antagonizing apoptosis-resistance pathways, such as the PI3/Akt pathway, in combination with death receptor activation, may induce cell death in TRAIL-resistant glioma.

Indexed as

AminopyridinesAntineoplastic AgentsApoptosisAstrocytesBrain NeoplasmsCell Line, TumorDrug Resistance, NeoplasmDrug SynergismGliomaHumansMorpholinesProto-Oncogene Proteins c-bcl-2Receptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandUp-RegulationAminopyridinesAntineoplastic AgentsMorpholinesNVP-BKM120PMAIP1 protein, humanProto-Oncogene Proteins c-bcl-2Receptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTNFRSF10A protein, human

Identifiers

PMID26044191
PMCPMC4501659
OpenAlexW1568674516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.